The use of highly active antiretroviral therapy (HAART) has extremely enhanced the clinical
outcome of HIV disease with a decrease in mortality and morbidity. However, the inclusion of …

The introduction of highly active antiretroviral therapy (HAART) including nucleoside reverse
transcriptase inhibitors (NRTI) and protease inhibitors (PI) has dramatically improved the …

Acquired fat redistribution, that is, peripheral fat loss often accompanied by central fat
accumulation in patients with HIV infection is the most common form of lipodystrophy in man …

The introduction of highly active antiretroviral therapy (HAART) for the treatment of acquired
immunodeficiency syndrome (AIDS) has resulted in greater survival of patients infected with …

Peripheral lipodystrophy, central adiposity, hyperlipidaemia, insulin resistance, and diabetes
mellitus, in varying constellations, are frequent complications of highly active antiretroviral …

The development of efficacious antiretroviral drugs that minimize adverse effects is a current
challenge in HIV-1 therapy. Metabolic alterations reminiscent of the metabolic syndrome and …

Increasingly effective therapies for HIV infection are now available. These treatments,
referred to collectively as highly active antiretroviral therapy, comprise various combinations …

Subcutaneous atrophy and central fat accumulation are common among HIV-infected
patients receiving highly active antiretroviral therapy, and may be accompanied by …

HIV-associated lipodystrophy or lipoatrophy, unreported before the introduction of highly
active antiretroviral therapy (HAART), was first described in 1998, and has a prevalence …

The introduction of highly active antiretroviral therapy (HAART) has significantly improved
the clinical outcome of HIV disease with increased survival rates. However, some HAART …